RISPERIDONE - Generic Drug Details

What are the generic drug sources for risperidone and what is the scope of freedom to operate?

Risperidone is the generic ingredient in seven branded drugs marketed by Labs Farms Rovi Sa, Shandong Luye, Indivior, Janssen Pharms, Amneal, Nanomi, Teva Pharms Usa Inc, Amneal Pharms, Ani Pharms, Apozeal Pharms, Aurobindo Pharma Ltd, Chartwell Molecular, Hikma, Lannett Co Inc, Pharm Assoc, Precision Dose, Sun Pharma Canada, Tris Pharma Inc, Wockhardt Bio Ag, Teva, Actavis Labs Fl Inc, Chartwell Rx, Dash Pharms, Jubilant Generics, Ph Health, Sandoz, Senores Pharms, Sun Pharm Inds Ltd, Zydus Pharms Usa, Ajanta Pharma Ltd, Apotex Inc, Dr Reddys Labs Ltd, Heritage Pharma Avet, Ipca Labs Ltd, Jubilant Cadista, Novitium Pharma, Prinston Inc, Ratiopharm, Renata, Rising, Sun Pharm Inds Inc, Synthon Pharms, Torrent Pharms, Watson Labs, West Ward Pharms, and Zydus Pharms Usa Inc, and is included in fifty-six NDAs. There are thirty-five patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Risperidone has three hundred and sixty-four patent family members in forty-three countries.

There are thirty drug master file entries for risperidone. Thirty-nine suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for RISPERIDONE

International Patents:	364
US Patents:	35
Tradenames:	7
Applicants:	46
NDAs:	56
Drug Master File Entries:	30
Finished Product Suppliers / Packagers:	39
Raw Ingredient (Bulk) Api Vendors:	143
Clinical Trials:	572
Drug Prices:	Drug price trends for RISPERIDONE
Drug Sales Revenues:	Drug sales revenues for RISPERIDONE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RISPERIDONE
What excipients (inactive ingredients) are in RISPERIDONE?	RISPERIDONE excipients list
DailyMed Link:	RISPERIDONE at DailyMed

See drug prices for RISPERIDONE

See drug sales revenues for RISPERIDONE

Recent Clinical Trials for RISPERIDONE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Hospital, Strasbourg, France	PHASE2
Northwell Health	PHASE4
National Institute of Mental Health (NIMH)	PHASE4

See all RISPERIDONE clinical trials

Generic filers with tentative approvals for RISPERIDONE

Applicant	Application No.	Strength	Dosage Form
		1MG/ML	SOLUTION; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for RISPERIDONE

Drug Class

Atypical Antipsychotic

Medical Subject Heading (MeSH) Categories for RISPERIDONE

Antipsychotic Agents

Dopamine Antagonists

Serotonin Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for RISPERIDONE

N05AX	Other antipsychotics
N05A	ANTIPSYCHOTICS
N05	PSYCHOLEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for RISPERIDONE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RISPERDAL	Orally Disintegrating Tablets	risperidone	0.25 mg	021444	1	2005-04-11
RISPERDAL	Orally Disintegrating Tablets	risperidone	3 mg and 4 mg	021444	1	2005-03-23

US Patents and Regulatory Information for RISPERIDONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zydus Pharms Usa Inc	RISPERIDONE	risperidone	TABLET;ORAL	078040-003	Oct 16, 2008	AB	RX	No	No
Teva	UZEDY	risperidone	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	213586-006	Apr 28, 2023		RX	Yes	Yes
Precision Dose	RISPERIDONE	risperidone	SOLUTION;ORAL	076797-001	Jun 28, 2010		DISCN	No	No
Shandong Luye	RYKINDO	risperidone	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	212849-003	Jan 13, 2023		RX	Yes	No			Y
Chartwell Molecular	RISPERIDONE	risperidone	TABLET;ORAL	077543-005	May 18, 2011	AB	RX	No	No
Indivior	PERSERIS KIT	risperidone	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	210655-001	Jul 27, 2018		RX	Yes	No
Sun Pharm Inds Ltd	RISPERIDONE	risperidone	TABLET, ORALLY DISINTEGRATING;ORAL	078464-005	Apr 8, 2013		DISCN	No	No

Expired US Patents for RISPERIDONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva	UZEDY	risperidone	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	213586-005	Apr 28, 2023
Janssen Pharms	RISPERDAL CONSTA	risperidone	POWDER;INTRAMUSCULAR	021346-003	Oct 29, 2003
Janssen Pharms	RISPERDAL	risperidone	TABLET, ORALLY DISINTEGRATING;ORAL	021444-005	Dec 23, 2004
Janssen Pharms	RISPERDAL CONSTA	risperidone	POWDER;INTRAMUSCULAR	021346-001	Oct 29, 2003
Janssen Pharms	RISPERDAL	risperidone	TABLET, ORALLY DISINTEGRATING;ORAL	021444-002	Apr 2, 2003
Janssen Pharms	RISPERDAL CONSTA	risperidone	POWDER;INTRAMUSCULAR	021346-001	Oct 29, 2003
Teva	UZEDY	risperidone	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	213586-004	Apr 28, 2023

EU/EMA Drug Approvals for RISPERIDONE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Laboratorios Farmacéuticos Rovi, S.A.	Okedi	risperidone	EMEA/H/C/005406Treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone.	Authorised	no	no	no	2022-02-14

International Patents for RISPERIDONE

Country	Patent Number	Title	Estimated Expiration
Canada	2624088
South Korea	20150015020
Japan	6302983
South Africa	201304687
Japan	2015143259	リスペリドン徐放性ミクロスフェア組成物 (RISPERIDONE SUSTAINED RELEASE MICROSPHERE COMPOSITION)
Canada	2800111
Chile	2013001942

Supplementary Protection Certificates for RISPERIDONE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0196132	94C0008	Belgium		PRODUCT NAME: RISPERIDONE; NAT REG.: 2 S 414 F 3 19940527; FIRST REG.: GB 0242/0186 19921208

RISPERIDONE: PATENT LANDSCAPE AND MARKET PROJECTIONS

Last updated: February 19, 2026

Risperidone, an atypical antipsychotic, has navigated a complex patent lifecycle and a dynamic market environment. Originally developed by Janssen Pharmaceutica, a Johnson & Johnson subsidiary, its primary patents have long expired, leading to extensive generic competition. This analysis details the patent history, current market status, and future financial trajectory of risperidone, providing insights for stakeholders in the pharmaceutical sector.

WHAT IS RISPERIDONE AND ITS THERAPEUTIC APPLICATIONS?

Risperidone is a selective monoamine antagonist that binds to serotonin 5-HT2 and dopamine D2 receptors with high affinity. Clinically, it is prescribed for the treatment of schizophrenia, bipolar I disorder (manic and mixed episodes), and irritability associated with autistic disorder in children and adults. Its efficacy in managing psychotic symptoms and behavioral disturbances underpins its sustained market presence, despite the advent of newer antipsychotic agents.

The drug is available in multiple formulations, including oral tablets, oral solutions, and long-acting injectable (LAI) formulations. The LAI formulations, such as Risperdal Consta, offer extended duration of action, improving patient adherence and therapeutic outcomes, and have historically commanded premium pricing and benefited from separate patent protection for their delivery systems.

WHEN WERE THE KEY PATENTS GRANTED AND WHAT WAS THEIR SCOPE?

The foundational patents for risperidone were filed in the late 1980s and granted in the early 1990s.

• U.S. Patent 4,804,663: This patent, granted on February 14, 1989, claimed the compound risperidone and related chemical structures. Its expiration marked the initial entry point for generic manufacturers in the United States. The patent term was 17 years from the grant date.
• U.S. Patent 5,206,371: Granted on April 27, 1993, this patent covered methods of treating psychiatric disorders using risperidone. This patent also expired, further opening the market to generic competition.
• Formulation and Delivery Patents: Additional patents were granted for specific formulations and delivery mechanisms. For instance, patents related to the long-acting injectable formulation (e.g., Risperdal Consta, involving microsphere technology) provided extended market exclusivity beyond the compound patents. These formulation patents often had later expiration dates, allowing the innovator company to maintain a degree of market exclusivity for its branded, advanced delivery systems for a longer period.

The precise expiration dates varied by country due to differences in patent law and potential extensions (e.g., for pediatric exclusivity). However, the core composition-of-matter patents for risperidone expired in the United States around 2006 and in Europe shortly thereafter.

WHAT IS THE CURRENT MARKET STATUS OF RISPERIDONE?

The market for risperidone is characterized by intense generic competition following the expiration of its primary patents.

• Generic Dominance: The vast majority of risperidone prescriptions are now filled with generic versions. This has led to significant price erosion compared to the peak pricing of the branded product, Risperdal.
• Market Share: While precise, real-time market share data is proprietary, generic risperidone collectively holds a substantial portion of the antipsychotic market, particularly in the oral formulations. The accessibility and lower cost of generics have ensured widespread adoption across healthcare systems.
• Branded Product Performance: Johnson & Johnson's branded risperidone products, particularly Risperdal Consta, continue to generate revenue, but their market share is constrained by generic alternatives and the introduction of newer long-acting injectable antipsychotics. The LAI segment, however, still represents a significant revenue stream for the branded product due to the complexity of its delivery technology and the benefits of sustained release.
• Sales Figures: Global sales data for risperidone is fragmented due to the multitude of generic manufacturers. However, aggregate sales of risperidone (including branded and generic) were estimated to be in the range of \$1.5 billion to \$2 billion annually in the years following significant patent expiries. Current annual sales are likely lower as newer agents gain traction, but generics maintain substantial volume.

WHO ARE THE MAJOR GENERIC MANUFACTURERS AND COMPETITORS?

Numerous pharmaceutical companies manufacture and market generic risperidone. This includes both global players and regional manufacturers.

• Key Players: Prominent generic manufacturers include Teva Pharmaceutical Industries, Mylan (now Viatris), Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, and Aurobindo Pharma. These companies have established robust supply chains and distribution networks for risperidone across major markets.
• Product Offerings: Generic manufacturers offer risperidone in various strengths and dosage forms, including tablets (1 mg, 2 mg, 3 mg, 4 mg) and oral solutions. Some may also offer generic versions of the long-acting injectable formulation, though the development and regulatory approval for these are more complex.
• Competitive Landscape: The competitive landscape is highly fragmented, characterized by price-based competition. Manufacturers focus on cost-efficient production and efficient market access to secure prescription volume.

WHAT ARE THE RECENT LEGAL CHALLENGES AND LITIGATION RELATED TO RISPERIDONE?

Risperidone has been a subject of patent litigation, particularly concerning the extended exclusivity of its long-acting injectable formulations.

• ANDA Litigation: Generic manufacturers seeking to market their versions of risperidone have often faced patent litigation from the innovator company (Johnson & Johnson/Janssen). This typically involves Abbreviated New Drug Application (ANDA) filings in the U.S. and challenges to existing patents.
• Patent Extensions and Challenges: Litigation has centered on the validity and infringement of patents covering formulation, manufacturing processes, and methods of use. For instance, challenges to patents protecting the microsphere technology used in Risperdal Consta have been significant.
• Settlement Agreements: Many patent disputes are resolved through settlement agreements, which may include provisions for authorized generic entry or deferred generic launch dates. These agreements can significantly impact the timing and competitive intensity of generic market entry.

WHAT ARE THE FINANCIAL PROJECTIONS FOR RISPERIDONE?

The financial trajectory of risperidone is largely dictated by the dynamics of the generic market and the evolving therapeutic landscape.

• Continued Generic Growth (Volume-Based): While price erosion is a constant factor, the volume of risperidone prescriptions is expected to remain substantial due to its established efficacy, affordability, and inclusion on essential medicines lists globally. Generic sales will continue to be volume-driven.
• Declining Revenue (Value-Based): The overall market value for risperidone will likely continue to decline or remain stable at lower levels due to intense price competition among generic manufacturers. The shift from branded to generic will inherently reduce the total revenue generated by the drug class.
• Impact of New Therapies: The introduction of newer atypical antipsychotics, including those with novel mechanisms of action or improved side-effect profiles, will continue to divert market share from older medications like risperidone, particularly in treatment-naïve populations.
• Long-Acting Injectables (LAI) Segment: The LAI segment for risperidone (e.g., generic versions of Risperdal Consta) may offer more stable revenue streams compared to oral formulations due to higher development costs and pricing power associated with depot injections. However, this segment also faces competition from newer LAI antipsychotics.
• Emerging Markets: Growth in emerging markets may offer some expansion opportunities for generic risperidone as healthcare access improves and cost-effectiveness becomes a primary consideration.

Metric	Historical Context (Peak Branded)	Current Status (Generic Dominated)	Projected Trajectory (Next 5 Years)
Global Revenue	\$2-3 billion (2000s)	\$1-1.5 billion (aggregate)	Stable to slight decline
Average Selling Price (Oral)	High	Very Low	Further erosion
Average Selling Price (LAI)	Premium	Moderate (generics) to High (branded)	Stable to moderate decline
Volume of Prescriptions	High	Very High	Stable to slight increase
Market Share	Branded dominance	Generic dominance	Continued generic dominance

Source: Analyst estimates based on historical market data and industry reports.

WHAT ARE THE KEY FACTORS INFLUENCING THE FUTURE MARKET?

Several factors will shape the future market for risperidone.

• Healthcare Policy and Reimbursement: Government policies regarding drug pricing, reimbursement rates for generics, and formulary placement will significantly influence market access and pricing.
• Clinical Guidelines and Prescribing Trends: Evolving clinical guidelines for schizophrenia and bipolar disorder treatment, as well as physician prescribing preferences for newer agents, will impact risperidone's market share.
• Generic Price Wars: Intense competition among generic manufacturers will continue to drive down prices, impacting overall market value.
• Availability of Biosimilars/Complex Generics: The success and availability of complex generic versions of long-acting injectables will be a critical factor in that segment of the market.
• Patent Expirations of Newer Drugs: As newer antipsychotics face their own patent expiries, they will enter the generic market, potentially increasing competition for all antipsychotic medications, including risperidone.

KEY TAKEAWAYS

Risperidone's market is now primarily driven by generic competition following the expiry of its core patents. While overall market value is constrained by price erosion, prescription volumes remain high due to the drug's established efficacy and affordability. The long-acting injectable formulations continue to offer a premium segment, though also facing genericization and competition from newer therapies. Future market performance will be shaped by healthcare policy, evolving clinical practices, and the competitive dynamics within the generic pharmaceutical landscape.

FAQS

• What is the primary reason for the significant price drop of risperidone since its market introduction? The primary reason is the expiration of its original patents, which allowed generic manufacturers to enter the market, leading to intense price competition.
• Are there any remaining patent protections that could limit generic entry for risperidone? While core composition-of-matter patents have expired, specific patents related to formulations, manufacturing processes, or extended-release mechanisms (particularly for LAI versions) may still be in effect or subject to ongoing litigation, potentially delaying or limiting generic entry for certain product types.
• How does the availability of newer antipsychotic drugs affect the market for risperidone? Newer antipsychotic drugs offer alternative treatment options, potentially with improved side-effect profiles or novel mechanisms of action. Their availability can lead to market share erosion for older drugs like risperidone, especially in treatment-naïve patient populations or those not responding optimally to risperidone.
• What is the outlook for risperidone's long-acting injectable (LAI) formulations in the generic market? The LAI market for risperidone presents a more complex generic landscape due to the technical challenges in developing bioequivalent formulations. Generic versions of LAI risperidone are available and compete with the branded product, but their development and market penetration may differ from oral generics.
• In which geographic regions is risperidone most widely prescribed today, considering its generic status? Risperidone is widely prescribed globally, with high prescription volumes in developed markets (e.g., North America, Europe) where generic substitution is common, and increasingly in emerging markets where cost-effectiveness is a critical factor in drug selection.

CITATIONS

[1] U.S. Patent 4,804,663. (1989). Benzisoxazole derivatives. Retrieved from USPTO database. [2] U.S. Patent 5,206,371. (1993). Method for treating psychiatric disorders. Retrieved from USPTO database. [3] Johnson & Johnson. (Annual Reports). Form 10-K Filings. U.S. Securities and Exchange Commission. (Specific filings detailing sales and patent-related information for risperidone products). [4] Various Pharmaceutical Industry Analyst Reports. (2010-2023). Market analysis for antipsychotic medications. (Proprietary market research reports). [5] Generic Pharmaceutical Association (GPhA). (Various publications). Reports on the impact of generic competition.